We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.68B
AUM Growth
-$109M
Cap. Flow
-$70.1M
Cap. Flow %
-4.17%
Top 10 Hldgs %
48.34%
Holding
155
New
26
Increased
23
Reduced
13
Closed
37

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$26.4M
2
VTYX
Ventyx Biosciences
VTYX
+$20.8M
3
CBIO
Crescent Biopharma
CBIO
+$19.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$18.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$16.2M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$30.4M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.4M
3
ONC
BeOne Medicines Ltd
ONC
+$23.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.97%
2 Consumer Discretionary 5.18%
3 Financials 0.37%
4 Real Estate 0.31%
5 Technology 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
26
DELISTED
Ventyx Biosciences
VTYX
$17.9M 1.07%
+535,812
New +$20.8M
OMGA
27
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$15.3M 0.91%
2,533,045
+259,515
+11% +$1.81M
VOR icon
28
Vor Biopharma
VOR
$1.06B
$15M 0.89%
139,640
-4,139
-3% -$459K
FATE icon
29
Fate Therapeutics
FATE
$275M
$14.8M 0.88%
2,600,000
– –
ERAS icon
30
Erasca
ERAS
$6.15B
$14.2M 0.84%
4,721,194
+10,512
+0.2% +$38.2K
RXDX
31
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$13.1M 0.78%
+121,756
New +$14M
WVE icon
32
Wave Life Sciences
WVE
$1.12B
$13M 0.77%
3,000,000
– –
VRDN icon
33
Viridian Therapeutics
VRDN
$2.2B
$12.8M 0.76%
+504,978
New +$16.2M
GBIO
34
DELISTED
Generation Bio
GBIO
$12.1M 0.72%
281,419
– –
GERN icon
35
Geron
GERN
$898M
$12.1M 0.72%
+5,565,889
New +$15.8M
TVTX icon
36
Travere Therapeutics
TVTX
$5.17B
$11.5M 0.68%
511,784
+11,784
+2% +$250K
NTRA icon
37
Natera
NTRA
$36.4B
$11.1M 0.66%
200,000
– –
AUPH icon
38
Aurinia Pharmaceuticals
AUPH
$1.95B
$11M 0.65%
1,000,000
– –
CBIO
39
Crescent Biopharma
CBIO
$546M
$10.8M 0.64%
+85,891
New +$19.3M
FHTX icon
40
Foghorn Therapeutics
FHTX
$278M
$10.7M 0.63%
1,720,720
– –
NTLA icon
41
Intellia Therapeutics
NTLA
$1.51B
$10.3M 0.61%
276,077
+1,077
+0.4% +$42.2K
ALPN
42
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.21M 0.55%
1,193,030
– –
ARAV
43
DELISTED
Aravive, Inc. Common Stock
ARAV
$9.14M 0.54%
4,572,515
– –
MRSN
44
DELISTED
Mersana Therapeutics
MRSN
$9.11M 0.54%
88,632
+632
+0.7% +$88.7K
REPL icon
45
Replimune Group
REPL
$454M
$8.83M 0.52%
500,000
-200,000
-29% -$4.76M
BBIO icon
46
BridgeBio Pharma
BBIO
$16.4B
$8.29M 0.49%
500,000
+250,000
+100% +$2.92M
RNAM
47
DELISTED
Avidity Biosciences
RNAM
$7.86M 0.47%
511,962
+11,962
+2% +$263K
TGTX icon
48
TG Therapeutics
TGTX
$8.19B
$7.69M 0.46%
+511,389
New +$7.77M
TSVT
49
DELISTED
2seventy bio
TSVT
$7.65M 0.45%
+750,000
New +$8.57M
ETNB
50
DELISTED
89bio
ETNB
$7.62M 0.45%
500,000
+100,000
+25% +$1.3M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2023 Portfolio in Review

As of Q1 2023, Artal Group held 155 positions worth $1.68B, down 6.1% from $1.79B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $70.1M in Q1 2023, closing 37 positions and reducing 13 holdings. Its most notable exit was BELLUS Health Inc., an estimated $30.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Ventyx Biosciences worth $17.9M.

  • Artal Group's largest Q1 2023 buy was Ventyx Biosciences: 535,812 shares worth $17.9M.
  • Artal Group added most to Revolution Medicines in Q1 2023, an estimated $26.4M increase.
  • Artal Group's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $28.4M.
  • Artal Group fully exited BELLUS Health Inc. in Q1 2023, selling an estimated $30.4M.
  • Artal Group's ten largest holdings make up 48% of its $1.68B portfolio in Q1 2023.
  • Artal Group opened 26 new positions and closed 37 in Q1 2023.
  • Artal Group's portfolio value fell 6.1% quarter-over-quarter to $1.68B.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.